欢迎来到速发表网,咨询电话:400-838-9661

关于我们 登录/注册 购物车(0)

首页 > SCI期刊 > 医学 > Neurology And Therapy

Neurology And Therapy

评价信息:

影响因子:--

年发文量:53

神经病学和治疗 SCIESCI

Neurology And Therapy

《神经病学和治疗》(Neurology And Therapy)是一本以CLINICAL NEUROLOGY综合研究为特色的国际期刊。该刊由SPRINGER LONDON LTD出版商刊期4 issues per year。该刊已被国际重要权威数据库SCIE、SCI收录。期刊聚焦CLINICAL NEUROLOGY领域的重点研究和前沿进展,及时刊载和报道该领域的研究成果,致力于成为该领域同行进行快速学术交流的信息窗口与平台。该刊2022年影响因子为3.7。CiteScore指数值为5.40。

投稿咨询 加急发表

期刊简介预计审稿时间:6 Weeks

Aims and Scope

Neurology and Therapy aims to provide reliable and inclusive, rapid publication for all therapy related research for neurological indications, supporting the timely dissemination of research with a global reach, to help advance scientific discovery and support clinical practice.

Neurology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of neurological and psychiatric therapies, (also covering surgery and devices). Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial designs, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Neurology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

Rapid Publication

The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted, it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model, this allows for the rapid and efficient communication of the latest research and reviews to support scientific discovery and clinical practice.

Open Access

All articles published by Neurology and Therapy are open access.

Personal Service

The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts.

Digital Features and Plain Language Summaries

Neurology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.

For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/

Publication Fees

Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis.

Peer Review Process

Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.

At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviews conflict, an Editorial Board Member will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed. Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments, if appropriate.

Preprints

We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals.

Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550

Copyright

Neurology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.

Contact

For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.

《Neurology And Therapy》(神经病学和治疗)编辑部通讯方式为236 GRAYS INN RD, 6TH FLOOR, LONDON, ENGLAND, WC1X 8HL。如果您需要协助投稿或润稿服务,您可以咨询我们的客服老师。我们专注于期刊投稿服务十年,熟悉发表政策,可为您提供一对一投稿指导,避免您在投稿时频繁碰壁,节省您的宝贵时间,有效提升发表机率,确保SCI检索(检索不了全额退款)。我们视信誉为生命,多方面确保文章安全保密,在任何情况下都不会泄露您的个人信息或稿件内容。

中科院分区

2022年12月升级版

大类学科 分区 小类学科 分区 Top期刊 综述期刊
医学 3区 CLINICAL NEUROLOGY 临床神经病学 3区

2021年12月基础版

大类学科 分区 小类学科 分区 Top期刊 综述期刊
医学 2区 CLINICAL NEUROLOGY 临床神经病学 2区

2021年12月升级版

大类学科 分区 小类学科 分区 Top期刊 综述期刊
医学 3区 CLINICAL NEUROLOGY 临床神经病学 4区
名词解释:

基础版:即2019年12月17日,正式的《2019年中国科学院文献情报中心期刊分区表》;将JCR中所有期刊分为13个大类,期刊范围只有SCI期刊。

升级版:即2020年1月13日,正式的《2019年中国科学院文献情报中心期刊分区表升级版(试行)》,升级版采用了改进后的指标方法体系对基础版的延续和改进,影响因子不再是分区的唯一或者决定性因素,也没有了分区的IF阈值期刊由基础版的13个学科扩展至18个,科研评价将更加明确。期刊范围有SCI期刊、SSCI期刊。从2022年开始,分区表将只升级版结果,不再有基础版和升级版之分,基础版和升级版(试行)将过渡共存三年时间。

JCR分区

2021-2022年最新版JCR分区等级:Q2

JCR学科 分区
CLINICAL NEUROLOGY Q2
Gold OA文章占比 研究类文章占比 文章自引率
98.72% 83.50% 0.04...
开源占比 出版国人文章占比 OA被引用占比
0.98... -- 1

名词解释:JCR分区在学术期刊评价、科研成果展示、科研方向引导以及学术交流与合作等方面都具有重要的价值。通过对期刊影响因子的精确计算和细致划分,JCR分区能够清晰地反映出不同期刊在同一学科领域内的相对位置,从而帮助科研人员准确识别出高质量的学术期刊。

CiteScore 指数

CiteScore SJR SNIP CiteScore 指数
5.40 0.923 1.176
学科类别 分区 排名 百分位
大类:Medicine 小类:Neurology (clinical) Q2 124 / 373

66%

大类:Medicine 小类:Neurology Q2 62 / 175

64%

名词解释:CiteScore是基于Scopus数据库的全新期刊评价体系。CiteScore 2021 的计算方式是期刊最近4年(含计算年度)的被引次数除以该期刊近四年发表的文献数。CiteScore基于全球最广泛的摘要和引文数据库Scopus,适用于所有连续出版物,而不仅仅是期刊。目前CiteScore 收录了超过 26000 种期刊,比获得影响因子的期刊多13000种。被各界人士认为是影响因子最有力的竞争对手。

数据趋势图

历年中科院分区趋势图

历年IF值(影响因子)

历年引文指标和发文量

历年自引数据

发文数据

2019-2021年国家/地区发文量统计

国家/地区 数量
USA 73
England 26
Italy 18
GERMANY (FED REP GER) 17
Canada 12
Switzerland 11
Brazil 7
France 7
Sweden 7
Japan 6

2019-2021年机构发文量统计

机构 数量
UNIVERSITY OF LONDON 9
HARVARD UNIVERSITY 8
BIOGEN 7
CLEVELAND CLINIC FOUNDATION 6
BETH ISRAEL DEACONESS MEDICAL CENTER 5
CREIGHTON UNIVERSITY 5
NOVARTIS 5
PFIZER 5
SANOFI-AVENTIS 5
STATE UNIVERSITY SYSTEM OF FLORIDA 5

2019-2021年文章引用数据

文章引用名称 引用次数
Vitamin D and Multiple Sclerosis: A Comp... 39
A Systematic Review and Meta-Analysis of... 15
Emerging Immunotherapies for Parkinson D... 14
Antipsychotic-Related Movement Disorders... 13
Fingolimod Rebound: A Review of the Clin... 11
A Review of Dementia with Lewy Bodies' I... 9
Phase 1 Parkinson's Disease Studies Show... 9
Salivary Biomarkers for Alzheimer's Dise... 9
Fingolimod Immune Effects Beyond Its Seq... 8
A Review on MS-Based Blood Biomarkers fo... 8

相关期刊

免责声明

若用户需要出版服务,请联系出版商:236 GRAYS INN RD, 6TH FLOOR, LONDON, ENGLAND, WC1X 8HL。